KR102741265B1 - 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물 - Google Patents

미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물 Download PDF

Info

Publication number
KR102741265B1
KR102741265B1 KR1020207018744A KR20207018744A KR102741265B1 KR 102741265 B1 KR102741265 B1 KR 102741265B1 KR 1020207018744 A KR1020207018744 A KR 1020207018744A KR 20207018744 A KR20207018744 A KR 20207018744A KR 102741265 B1 KR102741265 B1 KR 102741265B1
Authority
KR
South Korea
Prior art keywords
human
akkermansia
article
abundance
hmo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207018744A
Other languages
English (en)
Korean (ko)
Other versions
KR20200091438A (ko
Inventor
루이스 크리스틴 비그스내스
브루스 맥코넬
Original Assignee
글리콤 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글리콤 에이/에스 filed Critical 글리콤 에이/에스
Publication of KR20200091438A publication Critical patent/KR20200091438A/ko
Application granted granted Critical
Publication of KR102741265B1 publication Critical patent/KR102741265B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020207018744A 2017-11-30 2018-11-30 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물 Active KR102741265B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201700680 2017-11-30
DKPA201700680 2017-11-30
DKPA201700690 2017-12-05
DKPA201700690 2017-12-05
PCT/IB2018/059501 WO2019106620A1 (en) 2017-11-30 2018-11-30 Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation

Publications (2)

Publication Number Publication Date
KR20200091438A KR20200091438A (ko) 2020-07-30
KR102741265B1 true KR102741265B1 (ko) 2024-12-11

Family

ID=66664406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207018744A Active KR102741265B1 (ko) 2017-11-30 2018-11-30 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물

Country Status (7)

Country Link
US (1) US20200323921A1 (cg-RX-API-DMAC7.html)
EP (1) EP3716983A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021504420A (cg-RX-API-DMAC7.html)
KR (1) KR102741265B1 (cg-RX-API-DMAC7.html)
CN (1) CN111683665A (cg-RX-API-DMAC7.html)
BR (1) BR112020010843A2 (cg-RX-API-DMAC7.html)
WO (1) WO2019106620A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
JP2022513524A (ja) 2018-12-19 2022-02-08 グリコム・アクティーゼルスカブ 低fodmap食を使用してヒトを治療するための組成物および方法
US20220054515A1 (en) * 2018-12-21 2022-02-24 Glycom A/S Composition and method for promoting intestinal barrier healing
EP3980025A4 (en) * 2019-06-05 2023-06-14 Glycom A/S HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-CELIAC GLUTEN AND/OR WHEAT SENSITIVITY
AU2020354581A1 (en) * 2019-09-24 2022-03-03 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
WO2021094993A1 (en) * 2019-11-14 2021-05-20 Glycom A/S Synthetic composition for balancing the bile acid profile in the intestine
US11331329B2 (en) 2020-05-13 2022-05-17 Glycosyn LLC Fucosylated oligosaccharides for prevention of coronavirus infection
EP4149482A4 (en) 2020-05-13 2024-05-22 Glycosyn LLC 2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION
US11896603B2 (en) * 2020-06-12 2024-02-13 The Regents Of The University Of California Oligosaccharide as therapeutic agent for alcohol associated liver disease
JP2023536090A (ja) * 2020-07-31 2023-08-23 アボット・ラボラトリーズ 脂肪肝疾患を予防、低減または遅延させる方法
WO2022117829A1 (en) * 2020-12-04 2022-06-09 Société des Produits Nestlé S.A. Compositions comprising human milk oligosaccharides for use in a subject to support night sleep duration
KR102456307B1 (ko) * 2021-11-10 2022-10-19 충남대학교산학협력단 3’-시알릴락토오스, 6’-시알릴락토오스 또는 이의 염을 유효성분으로 포함하는 감염에 의한 다발성 장기부전의 예방 또는 치료용 조성물
JP2023096870A (ja) * 2021-12-27 2023-07-07 株式会社明治 アッカーマンシア属細菌の増殖促進剤
US20260165955A1 (en) 2022-03-18 2026-06-18 Meiji Co., Ltd. Composition for controlling growth of bacteria of the genus collinsella and use thereof
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途
WO2024126578A1 (en) * 2022-12-13 2024-06-20 Dsm Ip Assets B.V. Synthetic composition comprising a human milk oligosaccharide for microbiota modulation
CN119138609B (zh) * 2024-11-19 2025-02-25 飞鹤(吉林)乳品有限公司 母乳低聚糖改善母婴肠道菌群的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055944A2 (en) * 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
EP2439264B1 (en) * 2010-10-11 2015-06-03 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
MX356184B (es) * 2010-12-31 2018-05-17 Abbott Lab Fórmulación pediátrica sintética que comprende un probiótico.
AU2012215042B2 (en) * 2011-02-10 2016-01-14 Société des Produits Nestlé S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用
NL2007268C2 (en) * 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
US10639319B2 (en) * 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MX2014012362A (es) * 2012-04-13 2015-05-07 Trustees Boston College Composición prebiótica y métodos de uso.
EP2842560A4 (en) * 2012-04-23 2015-12-02 Univ Kyoto COMPOSITION TO PROMOTE THE GROWTH OF BIFIDOBAKTERIA
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
CN107108677B (zh) * 2014-10-24 2020-08-07 格礼卡姆股份公司 Hmo的混合物
US20170258820A1 (en) * 2014-10-29 2017-09-14 Glycom A/S Synthetic composition and method for promoting mucosal healing
US20160287637A1 (en) * 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US10881674B2 (en) * 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
MX378680B (es) * 2015-03-05 2025-03-11 Soc Des Produits Nestle S A Star Composiciones para usar en la prevencion o el tratamiento de infecciones/inflamaciones gastrointestinales en infantes o niños pequeños.
US10537597B2 (en) * 2015-10-05 2020-01-21 Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos Use of Akkermansia muciniphila for treating inflammatory conditions
US10780103B2 (en) * 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
CN108471793A (zh) * 2016-01-26 2018-08-31 雀巢产品技术援助有限公司 用于婴儿或幼儿以预防或治疗变态反应的包含人乳低聚糖的组合物
EP3589139A4 (en) * 2017-03-01 2020-12-23 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
WO2018207110A1 (en) * 2017-05-09 2018-11-15 Glycom A/S Synthetic composition for microbiota modulation
US20180333426A1 (en) * 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
US11541068B2 (en) * 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing autism spectrum disorder symptoms
EP3743078A4 (en) * 2017-12-22 2022-01-19 Glycom A/S COMPOSITION WITH HMOs TO PREVENT OR REDUCE NOCICEPTION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Also Published As

Publication number Publication date
JP2021504420A (ja) 2021-02-15
US20200323921A1 (en) 2020-10-15
WO2019106620A1 (en) 2019-06-06
CN111683665A (zh) 2020-09-18
KR20200091438A (ko) 2020-07-30
EP3716983A1 (en) 2020-10-07
EP3716983A4 (en) 2022-03-02
BR112020010843A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
US11696921B2 (en) Synthetic composition for microbiota modulation
US11529365B2 (en) Synthetic composition for microbiota modulation
US20200323921A1 (en) Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation
US11291677B2 (en) Synthetic composition for microbiota modulation
US11278558B2 (en) Synthetic composition for microbiota modulation
US11998558B2 (en) Synthetic composition for treating antibiotic associated complications
US11541067B2 (en) HMO compositions and methods for reducing detrimental proteolytic metabolites
JP2017533915A (ja) 過敏性腸症候群の治療のための合成組成物および方法
US20220378809A1 (en) Synthetic composition for balancing the bile acid profile in the intestine
EP3630124A1 (en) Synthetic composition comprising oligosaccharides and its use in medical treatment.
US11554131B2 (en) Mixture of HMOs for treating autoimmune diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601